A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : LF / lymphatic filariasis

[Related PubMed/MEDLINE]
Total Number of Papers: 478
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   LF  (>> Co-occurring Abbreviation)
Long Form:   lymphatic filariasis
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A surveillance system for lymphatic filariasis after its elimination in Sri Lanka. CFA, mf
2019 Association of a PD-L2 Gene Polymorphism with Chronic Lymphatic Filariasis in a South Indian Cohort. CI, CP, EN, IL, OR, PD, PD-L, SNPs
2019 Bridging the gap in outreach and compliance with mass drug administration for lymphatic filariasis elimination in an endemic district in Kerala, India: an intervention research approach. MDA, SGWN
2019 Elimination of lymphatic filariasis as a public health problem in Niue under PacELF, 1999-2016. DEC, ICT, MDA, WPRO
2019 Elimination within reach: A cross-sectional study highlighting the factors that contribute to persistent lymphatic filariasis in eight communities in rural Ghana. MDA, mf
2019 Epidemiological screening and xenomonitoring for human lymphatic filariasis infection in select districts in the states of Maharashtra and Karnataka, India. MDA
2019 Integrated seroprevalence-based assessment of Wuchereria bancrofti and Onchocerca volvulus in two lymphatic filariasis evaluation units of Mali with the SD Bioline Onchocerciasis/LF IgG4 Rapid Test. EU, ICT, TAS
2019 Mapping of lymphatic filariasis in loiasis areas: A new strategy shows no evidence for Wuchereria bancrofti endemicity in Cameroon. mf
2019 Non-compliance to mass drug administration associated with the low perception of the community members about their susceptibility to lymphatic filariasis in Ankobra, Ghana. MDA
10  2019 Preventive chemotherapy reverses covert, lymphatic-associated tissue change in young people with lymphatic filariasis in Myanmar. BIS, MDA, PC
11  2018 A comparison between paper-based and m-Health tools for collating and reporting clinical cases of lymphatic filariasis and podoconiosis in Ethiopia. HEWs, IU, MMDP
12  2018 A Delphi consultation to assess indicators of readiness to provide quality health facility-based lymphoedema management services. MMDP, SD, WHO
13  2018 Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature. AEs, ALB, DEC, IVM, MDA
14  2018 An assessment of mosquito collection techniques for xenomonitoring of anopheline-transmitted Lymphatic Filariasis in Ghana. AGT, IRC
15  2018 Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models. DA, IA, IDA, MDA, mf
16  2018 Assessing knowledge about lymphatic filariasis and the implementation of mass drug administration amongst drug deliverers in three districts/cities of Indonesia. MDA
17  2018 Assessing the feasibility of integration of self-care for filarial lymphoedema into existing community leprosy self-help groups in Nepal. SHGs
18  2018 Building Trust through Lymphatic Filariasis Elimination: A Platform to Address Social Exclusion and Human Rights in the Dominican Republic. DR, NTD
19  2018 Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis. AEs, CFA
20  2018 Comparison of antigen and antibody responses in repeat lymphatic filariasis transmission assessment surveys in American Samoa. CFA, LIPS, MDA, TAS
21  2018 Comprehensive Assessment of a Hotspot with Persistent Bancroftian Filariasis in Coastal Sri Lanka. CI
22  2018 Current epidemiological evidence for predisposition to high or low intensity human helminth infection: a systematic review. ---
23  2018 Determinants of transmission hotspots and filarial infection in households after eight rounds of mass drug administration in India. MDA
24  2018 Development of an urban molecular xenomonitoring system for lymphatic filariasis in the Recife Metropolitan Region, Brazil. CDC, MMRR, MX, RMR
25  2018 Effects of lyophilization and storage temperature on Wuchereria bancrofti antigen sensitivity and stability. DBS, QC
26  2018 Electrochemical immunosensor for differential diagnostic of Wuchereria bancrofti using a synthetic peptide. ALT-2, SPCE
27  2018 Elimination of lymphatic filariasis as a public health problem from the Cook Islands. DEC, MDA, PacELF, WHO
28  2018 Elimination of lymphatic filariasis: current perspectives on mass drug administration. GPELF, MDA, NTDs
29  2018 Emotional Difficulties and Experiences of Stigma among Persons with Lymphatic Filariasis in Plateau State, Nigeria. ---
30  2018 Environmental suitability for lymphatic filariasis in Nigeria. ---
31  2018 Evaluating the Vaccine Potential of a Tetravalent Fusion Protein (rBmHAXT) Vaccine Antigen Against Lymphatic Filariasis in a Mouse Model. GLA/SE, MCA
32  2018 Evaluation of the recombinant antigens Wb14 and WbT for the capture antibody diagnosis of lymphatic filariasis. CP, ELISA, EN, GPELF, MF, NE
33  2018 Feasibility of school-based health education intervention to improve the compliance to mass drug administration for lymphatic Filariasis in Lalitpur district, Nepal: A mixed methods among students, teachers and health program manager. MDA, SBHE
34  2018 For as Long as Necessary: Examining 30 years of MSD's Focus on Achieving Elimination of Onchocerciasis and Lymphatic Filariasis. ESPEN, MDP
35  2018 GEOFIL: A spatially-explicit agent-based modelling framework for predicting the long-term transmission dynamics of lymphatic filariasis in American Samoa. ---
36  2018 How elimination of lymphatic filariasis as a public health problem in the Kingdom of Cambodia was achieved. MDA, NTDs
37  2018 Human infection with sub-periodic Brugia spp. in Gampaha District, Sri Lanka: a threat to filariasis elimination status? AFC, BRT, MDA, mf, NBS, SA
38  2018 Identification and characterization of Loa loa antigens responsible for cross-reactivity with rapid diagnostic tests for lymphatic filariasis. RDTs
39  2018 Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns. CDTI, IDA, SAEs, SSA
40  2018 Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance - American Samoa, 2016. CFA, MDA, TAS
41  2018 Immune Response to Brugia malayi Asparaginyl-tRNA Synthetase in Balb/c Mice and Human Clinical Samples of Lymphatic Filariasis. AARS, BmAsnRS, FoxP3, rBmAsnRS
42  2018 Impact of Ivermectin Mass Drug Administration for Lymphatic Filariasis on Scabies in Eight Villages in Kongwa District, Tanzania. CI, MDA
43  2018 Impact of two follow-up schemes on morbidity management and disability prevention (MMDP) programme for filarial lymphedema in Matara, Sri Lanka. CHBC, DFU, EL, MFU, MMDP
44  2018 Increasing evidence of low lymphatic filariasis prevalence in high risk Loa loa areas in Central and West Africa: a literature review. ICT, MDA, SAEs, WHO
45  2018 Innovative Surveillance Strategies to Support the Elimination of Filariasis in Africa. NTDs, POCT, WHO
46  2018 Integrated morbidity mapping of lymphatic filariasis and podoconiosis cases in 20 co-endemic districts of Ethiopia. HEW, MMDP, NTDs
47  2018 Integrated risk mapping and landscape characterisation of lymphatic filariasis and loiasis in South West Nigeria. ICT, MDA, RAPLOA, SAEs
48  2018 Island-Wide Surveillance of Gastrointestinal Protozoan Infection on Fiji by Expanding Lymphatic Filariasis Transmission Assessment Surveys as an Access Platform. TAS
49  2018 Low Microfilaremia Levels in Three Districts in Coastal Ghana with at Least 16 Years of Mass Drug Administration and Persistent Transmission of Lymphatic Filariasis. GPELF, MDA
50  2018 Lymphatic filariasis control in Tanzania: infection, disease perceptions and drug uptake patterns in an endemic community after multiple rounds of mass drug administration. CFA, MDA, mf
51  2018 Lymphatic filariasis transmission in Rufiji District, southeastern Tanzania: infection status of the human population and mosquito vectors after twelve rounds of mass drug administration. CFA, ICTs, MDA, qPCR, TAS
52  2018 Mapping and modelling the impact of mass drug adminstration on filariasis prevalencein Myanmar. Ag, MDA, NPELF, TAS
53  2018 Molecular xenomonitoring for post-validation surveillance of lymphatic filariasis in Togo: no evidence for active transmission. ET, HLC, PSC
54  2018 Molecular xenomonitoring for Wuchereria bancrofti in Culex quinquefasciatus in two districts in Bangladesh supports transmission assessment survey findings. MDA, MX, TAS
55  2018 Morbidity management and disability prevention for lymphatic filariasis in Sri Lanka: Current status and future prospects. MDA, MMDP, SWOT
56  2018 Mosquitoes and the Lymphatic Filarial Parasites: Research Trends and Budding Roadmaps to Future Disease Eradication. MDA
57  2018 Multiplex serology for impact evaluation of bed net distribution on burden of lymphatic filariasis and four species of human malaria in northern Mozambique. LLINs, MDA, RDTs
58  2018 Perceived threat and benefit toward community compliance of filariasis' mass drug administration in Pekalongan district, Indonesia. HBM, MDA
59  2018 Progress on elimination of lymphatic filariasis in Sierra Leone. MDA, mf, pre-TAS
60  2018 Prospects of developing a prophylactic vaccine against human lymphatic filariasis - evaluation of protection in non-human primates. MDA, TPx-2
61  2018 Quantifying the value of surveillance data for improving model predictions of lymphatic filariasis elimination. MDAs, mf
62  2018 Rapid progress towards elimination of lymphatic filariasis in endemic regions of Myanmar as a result of 16years of anti-filarial activities (2001-2016). IUs, MDA
63  2018 Results of a confirmatory mapping tool for Lymphatic filariasis endemicity classification in areas where transmission was uncertain in Ethiopia. CFA, ICT, MDA
64  2018 Status of lymphatic filariasis with progression of age and gender & eradication strategies: A survey among residents of Hardoi district of Uttar Pradesh, an endemic region of North India. B. malayi, B. timori, MDA, W. bancrofti
65  2018 Surveillance for lymphatic filariasis after stopping mass drug administration in endemic districts of Togo, 2010-2015. FTS, MDA, PTS, TAS
66  2018 The Effect of a Regimen of Antifungal Cream Use on Episodes of Acute Adenolymphangitis (ADL) among Lymphedema Patients: An Application Using Marginal Structural Models. ADL
67  2018 The History of Bancroftian Lymphatic Filariasis in Australasia and Oceania: Is There a Threat of Re-Occurrence in Mainland Australia? ---
68  2018 The Prevalence of Lymphatic Filariasis in Elementary School Children Living in Endemic Areas: A Baseline Survey Prior to Mass Drug Administration in Pekalongan District-Indonesia. CFA, ES, ICT, MDA
69  2018 The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. MDA
70  2018 Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission. CFA, MDA, TAS
71  2018 Update on the current status of onchocerciasis in Cote d'Ivoire following 40 years of intervention: Progress and challenges. CDTI, CMFL
72  2018 Use of Antibody Tools to Provide Serologic Evidence of Elimination of Lymphatic Filariasis in The Gambia. CI, DBSs, ELISA
73  2017 A practical approach for scaling up the alternative strategy for the elimination of lymphatic filariasis in Loa loa endemic countries - developing an action plan. IU, MDA, SAEs
74  2017 An evaluation of Wb123 antibody elisa in individuals treated with ivermectin and albendazole, and implementation challenges in Africa. ELISA, ICT
75  2017 Antifilarial activity of caffeic acid phenethyl ester on Brugia pahangi in vitro and in vivo. CAPE, mf
76  2017 Application of a household-based molecular xenomonitoring strategy to evaluate the lymphatic filariasis elimination program in Tamil Nadu, India. EUs, MX
77  2017 Applying a mobile survey tool for assessing lymphatic filariasis morbidity in Mtwara Municipal Council of Tanzania. SMS
78  2017 Assessing endgame strategies for the elimination of lymphatic filariasis: A model-based evaluation of the impact of DEC-medicated salt. DEC, mf
79  2017 Assessment of lymphatic filariasis prior to re-starting mass drug administration campaigns in coastal Kenya. ICT, MDA, mf, NTDs, WHO
80  2017 Can Lymphatic Filariasis Be Eliminated by 2020? LD, NTD, SDGs
81  2017 Commentary: restarting NTD programme activities after the Ebola outbreak in Liberia. EVD, MDA, ONC, SCH
82  2017 Community-based field implementation scenarios of a short message service reporting tool for lymphatic filariasis case estimates in Africa and Asia. NTD, SMS
83  2017 Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial. ALB, DEC, GPELF, IVM, MDA
84  2017 Continental-scale, data-driven predictive assessment of eliminating the vector-borne disease, lymphatic filariasis, in sub-Saharan Africa by 2020. ---
85  2017 Criteria to Stop Mass Drug Administration for Lymphatic Filariasis Have Been Achieved Throughout Plateau and Nasarawa States, Nigeria. EUs, ICT, MDA, TAS
86  2017 Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration. Ab, MDA
87  2017 Detecting infection hotspots: Modeling the surveillance challenge for elimination of lymphatic filariasis. CS, ICT, MDA, PVP, SRS
88  2017 Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. ABZ, CFA, DEC, FDS, NP, PS
89  2017 First evidence of lymphatic filariasis transmission interruption in Cameroon: Progress towards elimination. CFA, EU, ICT, MDA, TAS, WHO
90  2017 Follow-up Study of Patients Previously Diagnosed with Lymphatic Filariasis in Korea. ---
91  2017 Future Research Priorities for Morbidity Control of Lymphedema. PSP
92  2017 How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis. MDA, NTD
93  2017 Impact of mass drug administration for elimination of lymphatic filariasis in Nepal. ALB, DEC, EUs, MDA, pre-TAS, TAS, WHO
94  2017 Impact of the Lymphatic Filariasis Control Program towards elimination of filariasis in Vanuatu, 1997-2006. MDA
95  2017 Improving the efficacy of a prophylactic vaccine formulation against lymphatic filariasis. MCA, MDA
96  2017 Low Level of Hepatitis B Virus Infection in Children 20 Years After Initiation of Infant Vaccination Program in Wallis and Futuna. HBsAg, HBV, HepB, HepB-BD, TAS, WAF
97  2017 Lymphatic filariasis elimination efforts in Rufiji, southeastern Tanzania: decline in circulating filarial antigen prevalence in young school children after twelve rounds of mass drug administration and utilization of long-lasting insecticide-treated nets. CFA, ICT, LLINs, MDA
98  2017 Lymphatic Filariasis in Mainland Southeast Asia: A Systematic Review and Meta-Analysis of Prevalence and Disease Burden. PDR
99  2017 Lymphatic Filariasis Increases Tissue Compressibility and Extracellular Fluid in Lower Limbs of Asymptomatic Young People in Central Myanmar. BIS
100  2017 Lymphatic filariasis patient identification in a large urban area of Tanzania: An application of a community-led mHealth system. LE, MMDP